29 March 2007

Preliminary results for year ended 31 December 2006

Cyprotex, a drug discovery technology and information company, today reports its preliminary results for the year ended 31 December 2006.

Highlights

• Cyprotex recorded its first quarterly net profit and generated cash from operational activities during the final three months of 2006
• Revenue increased by 30% to £3.5 million from £2.7 million
• Gross profits similarly rose by 30% to £3.0 million up from £2.3 million
• Despite continued investment in equipment and services, cash resources remained healthy at £0.46 million (2005: £0.69 million)
• Basic loss per share down to 0.48p (2005: loss 0.78p*)
• The rapid expansion of the Group’s customer base accelerated further during the second half as a result of the marketing push to gain greater penetration in the United States.

* Restated following the adoption of FRS20, (‘Share based payment’)

Commenting on the results, Robert Morrisson Atwater, Chairman and Chief Executive Officer of Cyprotex, said:

“2007 has started with great optimism. In meeting the demands of its exacting customer base, Cyprotex is now able to measure the global opportunity facing it. Management now expects to report a positive outcome for 2007.”

Download Cyprotex Preliminary Results for year ended 31 December 2006

For further information:

Cyprotex PLC
Robert Morrison Atwater, CEO
Tel: +44 (0)207 930 9030
ir@cyprotex.com
www.cyprotex.com

or

Russell Gibbs, CFO
Tel: +44 (0)207 930 9030
ir@cyprotex.com
www.cyprotex.com

Media Enquires:

WMC Communications
Charlie Geller/Alex Glover
Tel: +44 (0)20 7930 9030
charlie.geller@wmccommunications.com